Navigation Links
Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
Date:9/4/2007

tcVisualize(TM) 3.0 with Monte Carlo brings predictability to whole range

of Phase II, III and IV Clinical Trials

WAYLAND, Mass., Sept. 4 /PRNewswire/ -- Tourtellotte Solutions, a global leader in off-the-shelf and custom supply chain software for the biopharmaceutical, retail, and consumer goods industries, today announced the release of its tcVisualize(TM) 3.0 clinical trial supply simulator. The latest generation tcVisualize software now offers wide support for variable dosing, cross-protocol drug pooling, Monte Carlo simulations, and adaptive trial designs. Among many other enhancements, the 3.0 release also expands modeling up the supply chain to include pharmaceutical ingredients and other kit components.

The Monte Carlo capabilities of tcVisualize 3.0, developed with close involvement of some of the world's premiere bio-statisticians, increase the accuracy of modeling significantly - and are key to the support of adaptive trials. Monte Carlo statistical techniques allow the application to simulate a multiplicity of scenarios, weigh the possibilities, and deliver answers with high - and specific - degrees of confidence.

"I'm proud that our team was able to pack so many significant advances into a single release of tcVisualize," said Ed Tourtellotte, CEO of Tourtellotte Solutions. "We're giving clients broader functionality - and far greater power - than they can get anywhere else."

One of the most significant of tcVisualize 3.0's new features is its support of variable dosing (variable titration) trials, which are in increasing use by many biopharmaceuticals. tcVisualize 3.0 is the only tool that can model and compare scenarios around the intricacies of unpredictable dosing, allowing users to avoid the usual supply crises and excess overage.

Also new is tcVisualize 3.0's support of drug pooling, an emerging supply technique that reduces waste and minimizes risk by allowing supply and safety stock to be shared among protocols. tcVisualize 3.0 can be configured to simulate multiple studies simultaneously so that stock can be shared at specified depots and even sites.

One of tcVisualize 3.0's many smaller enhancements is its new ability to model the usage of active pharmaceutical ingredients (or any other constituent element) in dispensing units, and to report consumption at both the dispensing unit and constituent level. This is the first step in a direction that is of great interest to the industry: a clinical manufacturing demand plan at the enterprise level, driven by reliable study models. Tourtellotte Solutions will be pursuing this aggressively in future releases of tcVisualize.

For more information about Tourtellotte Solutions and the tcVisualize(TM) 3.0 product, please call David Diamond at 1.866.653.2770 x103, or visit http://www.tourtellottesolutions.com.

About Tourtellotte Solutions

Tourtellotte Solutions is a global leader in off-the-shelf and custom supply-chain software for the pharmaceutical, retail, and consumer goods markets. Tourtellotte Solutions' tcVisualize(TM), a groundbreaking clinical supply chain modeling and forecasting application for the pharmaceutical industry, is used by several of the largest pharmaceuticals. Tourtellotte also sells RockBlocks(R), which is widely used for managing sourcing in the retail, consumer goods, branded apparel, and footwear industries. Tourtellotte Solutions is a privately-held company headquartered in Wayland, Massachusetts.

Contacts: Karen Adelman

KBA Folio Communications

1.508.655.2128

k.adelman@kbafolio.com


'/>"/>
SOURCE Tourtellotte Solutions
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
2. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
3. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
6. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
7. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
8. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
9. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):